A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffuse large B-cell lymphoma

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2019
This article has no abstract
Epistemonikos ID: 0ce7beb69738bb1232ca629b5f617d435af50e7a
First added on: Jan 22, 2025